表皮生长因子受体在子宫内膜,早孕蜕膜及滋养细胞中？…

目的 了解表皮生长因子受体（ＥＧＦＲ）在子宫内细胞分化及发育中的作用。方法 采用免疫组织化学及逆转录－聚合酶链反应（ＲＴ－ＰＣＲ）技术测定５８例正常子宫内膜（３２例增生期，２６例分泌期）与２６例早孕蜕期。结果 ＥＧＦＲ存在于正常子人膜、早孕蜕膜腺体及间南细胞的细胞膜、核膜及胞浆内，分布均匀。ＥＧＦＲ还位于早剖解体及间质细胞核内。正常子宫内膜ＥＧＦＲ的表达，腺体部分高于间质部分，ＥＧＦＲ在增生期及分     

子宫内膜癌bcl-2癌基因的持续性表达及其临床意义

目的：研究子宫内膜癌ｂｃｌ－２癌基因的表达及其临床意义。方法：采用免疫组化ＡＢＣ法检测增生期、分泌期、单纯型增生、复合型增生及不典型增生子宫内膜共２６份，子宫内膜癌４９例的ｂｃｌ－２癌基因蛋白表达及雌、孕激素受体（ＥＲ、ＰＲ）的表达。结果：正常增生期子宫内膜、增生的子宫内膜存在ｂｃｌ－２的表达，与ＥＲ相关，分泌期子宫内膜ｂｃｌ－２表达下降；４９例子宫内膜癌中２６例ｂｃｌ－２表达阳性，占５３％，２９例ＥＲ表达阳性，占５９％，２５例ＰＲ表达阳性，占５１％。７２％ｂｃｌ－２表达阳性者ＥＲ阳性，７５％ｂｃｌ－２表达阴性者ＥＲ阴性（Ｐ＜０．０１）。６８％ｂｃｌ－２表达阳性者ＰＲ阳性，６２％ｂｃｌ－２阴性者ＰＲ阴性（Ｐ＜０．０５）。子宫内膜癌Ｇ１、Ｇ２级ｂｃｌ－２的表达率为６６％，显著高于Ｇ３级者（２１％）（Ｐ＜０．０５）。ｂｃｌ－２的表达与肌层浸润、手术分期无关，ｂｃｌ－２表达阳性及阴性者生存率统计差异无显著性。结论：子宫内膜ｂｃｌ－２的持续性表达与卵巢激素相互作用可能在子宫内膜癌发生、发展中起作用     

重复性早期自然流产病人非孕期血清激素水平和子宫内膜组织ER、PR含量变化的研究

用放免法测定了４０例拟诊为由内分泌病因所致的重复性早期自然流产病人卵泡期和黄体期的血清雌二醇（Ｅ２）、孕酮（Ｐ）、卵泡刺激素（ＦＳＨ）、促黄体生成素（ＬＨ）和血清催乳素（ＰＲＬ）水平，同时用生化法测定了相应增生期和分泌期子宫内膜组织中胞浆及胞核的雌、孕激素受体含量。通过和对照组比较，发现重复性早期自然流产病人黄体期和卵泡期的Ｅ２水平均显著低于对照组（Ｐ＜０．００５和Ｐ＜０．０５），其余各项激素水平与对照组无差异（Ｐ＞０．０５）；其子宫内膜增生期的胞浆雌激素受体（ＥＲｃ）含量显著低于对照组（Ｐ＜０．００５），分泌期子宫内膜的胞浆孕激素受体（ＰＲｃ）含量亦明显低于对照组（Ｐ＜０．０５）；各期子宫内膜组织的胞核雌、孕激素受体含量在两组间无差异。表明卵巢雌激素分泌不足和子宫内膜组织的受体含量减低是导致该组病人反复自然流产的原因。     

米非司酮抗早孕蜕膜雌,孕激素受体的免疫组织化学研究

目的了解米非司酮及米索前列醇（米索）对人早孕蜕膜雌激素受体（ＥＲ）、孕激素受体（ＰＲ）的影响。方法取正常早孕、服米非司酮及服米非司酮配伍米索后各１０例的蜕膜,应用单克隆抗体链菌素亲生物蛋白过氧化酶（ＳＰ）免疫组织化学方法及电子计算机图象分析技术,观察ＥＲ、ＰＲ的变化。结果正常早孕蜕膜ＥＲ和ＰＲ位于大部分蜕膜间质细胞及少数腺上皮细胞胞核内,受体水平积分ＥＲ为５８６０７９０±３１１６９１,ＰＲ为４９０５９７０±１５７３１９;服米非司酮后蜕膜ＥＲ、ＰＲ水平积分为３５４７１８０±１９１８５８、３７００７５０±１８８３２２;服米非司酮配伍米索后蜕膜ＥＲ和ＰＲ水平积分为２０２１７２１±１４５２８１、２５２８５８０±２４０５３５。３者间差异有显著性（Ｐ＜０．０５,Ｐ＜０．０１）。结论米非司酮及米索可使早孕蜕膜ＥＲ、ＰＲ水平下降,这可能与药物流产后子宫出血时间长有关。     

Foxp3在子宫内膜、正常早孕和原因不明复发性流产患者蜕膜上的表达

目的:探讨Foxp3在增生期、分泌期内膜和正常早孕、原因不明复发性流产(URSA)患者蜕膜的表达。方法:用免疫组化法观察15例增生期子宫内膜, 12例分泌期子宫内膜, 32例正常早孕和25例URSA患者蜕膜组织Foxp3的表达与分布。结果:增生期子宫内膜无Foxp3表达,分泌期内膜和蜕膜组织均有表达;分泌期内膜Foxp3的表达显著低于正常早孕组(P<0 .01)和URSA组(P<0. 05);URSA患者蜕膜Foxp3的表达显著低于正常早孕组(P<0 .01);Foxp3表达于胞浆,正常早孕组和分泌期内膜主要表达在腺上皮细胞,URSA患者主要表达在间质细胞。结论:Foxp3在分泌期子宫内膜和蜕膜组织的表达可能在胚泡植入和早期妊娠的维持中起重要作用,其表达水平降低可能与URSA的发生有关。     

AgNOR用于区别增生期与分泌期宫内膜的价值探讨

应用ＡｇＮＯＲ技术探讨正常子宫内膜增生期和分泌期中ＡｇＮＯＲ的分布及其用于区别增生期和分泌期宫内膜的可能性。方法：选择末次月经日期记载清楚的各期宫内膜标本共１２０例进行ＡｇＮＯＲ染色、计数。结果：在子宫内膜功能层腺上皮细胞的ＡｇＮＯＲ均数在增生晚期表达最高,增生期（３．５２±０．２４）与分泌期（１．４１±０．２８）相比差异具有极显著性（Ｐ＜０．００１）;间质细胞ＡｇＮＯＲ均数表现出两个高峰,一个为增生中期,一个为分泌晚期。结论：ＡｇＮＯＲ是判断子宫内膜分期的良好标志物。根据功能层腺上皮细胞和间质细胞ＡｇＮＯＲ计数,可以作为判断子宫内膜分期的重要指标。     

子宫肌瘤与肌肉组织雌孕激素受体含量与月经周期及子宫内膜组织相关系的探讨

应用放射受体分析法测定４０例子宫肌瘤患者子宫肌瘤、肌肉组织雌激素受体（ＥＲ）、孕激素受体（ＰＲ）的含量，月经周期根据月经史及子宫内膜组织相来判断，比较两种组织ＥＲ、ＰＲ含量与月经周期及子宫内膜组织相的关系。结果：子宫肌瘤组织的ＥＲ、ＰＲ含量高于同一子宫正常肌层的含量（Ｐ＜０．０５）；子宫肌瘤与肌肉两种组织中ＥＲ含量在子宫内膜增殖期高于分泌期（Ｐ＜０．０２５，Ｐ＜０．０５），ＰＲ含量分泌期高于增殖期（Ｐ＜０．０２５）。２３例有正常月经周期者，１５例与子宫内膜组织相符合，８例与子宫内膜组织相不符合。１５例无正常月经周期者，子宫内膜组织相多为增殖期改变，占８０％。提示：子宫肌瘤的发生、发展与雌、孕激素及其受体含量有关，孕激素在肿瘤发生、发展中可能起协同作用，提示抗孕激素治疗子宫肌瘤的可能性。     

CD44V6、EGFR在卵巢上皮癌中的表达及临床意义

目的：探讨ＣＤ４４Ｖ６及ＥＧＦＲ在卵巢上皮癌中的表达及临床意义。方法： 以 ＳＰ免疫组织化学方法检测 ３３５例卵巢上皮癌, １８例卵巢上皮瘤和 １５例正常卵巢组织石蜡标本 ＣＤ４４Ｖ６及 ＥＧＦＲ的表达,并分析卵巢上皮癌的临床病理资料。结果：①正常卵巢组织 ＣＤ４４Ｖ６及 ＥＧＦＲ均呈阴性表达,卵巢上皮瘤及上皮癌中均有中ＣＤ４４Ｖ６及ＥＧＦＲ表达,正常卵巢与卵巢良恶性肿瘤之间的表达差异有高度显著性（Ｐ＜０．０１）,卵巢上皮癌与卵巢上皮瘤之间的表达差异无显著性（Ｐ＞０．０５）;（２）ＣＤ４４Ｖ６及ＥＧＦＲ的阳性表达与卵巢上皮癌的临床分期有关（Ｐ＜０．０５）,与组织分化程度及病理类型无关（Ｐ＞０．０５）;③ＣＤ４４Ｖ６及ＥＧＦＲ的阳性表达与卵巢上皮癌预后有关（Ｐ＜０．０５）;④ＣＤ４４Ｖ６及ＥＧＦＲ在卵巢上皮癌中的表达差异无显著性（Ｐ＞０．０５）,二者具有相关性（Ｐ＜０．０５）．结论：ＤＤ４４Ｖ６及ＥＧＦＲ可能是卵巢上皮癌发生的相关基因,与肿瘤的发展及转移有关。检测 ＣＤ４４Ｖ６及 ＥＧＦＲ可以估计卵巢上皮癌患者的预后,指导化疗。     

胎盘组织中胰岛素样生长因子 -Ⅰ的定位及定量分析

目的探讨胎盘组织中胰岛素样生长因子Ⅰ（ＩＧＦⅠ）定位，评估ＩＧＦⅠ在胎儿生长发育中的作用。方法用免疫组化法对妊娠胎盘组织中ＩＧＦⅠ细胞进行定位，并采用计算机医学图像分析系统，检测小于胎龄儿（ＳＧＡ）组２２例，适于胎龄儿（ＡＧＡ）组２５例及大于胎龄儿（ＬＧＡ）组２５例的ＩＧＦⅠ，并进行定量分析。用ｔ检验法进行各组间均数检验。结果（１）胎盘ＩＧＦⅠ主要位于绒毛小叶的合体滋养细胞及细胞滋养细胞。此外，也存在于Ｈｏｆｂａｕｅｒ细胞及平滑绒毛层，但染色较以上两种细胞明显减弱，胎膜的羊膜细胞及蜕膜细胞偶尔可见阳性，而绒毛小叶蜕膜细胞则未见阳性着色。（２）与ＡＧＡ组比较，ＳＧＡ组胎盘ＩＧＦⅠ的相对面积及平均吸光度均显著降低（ｔ＝４．６５，Ｐ＜０．００１、ｔ＝２．１５，Ｐ＜０．０５），而ＬＧＡ组胎盘ＩＧＦⅠ的相对面积及平均吸光度均显著升高（ｔ＝８．７２，Ｐ＜０．００１；ｔ＝７．８２，Ｐ＜０．００１）。结论胎盘组织中ＩＧＦⅠ主要定位于胎盘小叶的合体滋养细胞、细胞滋养细胞；胎盘组织合成和分泌ＩＧＦⅠ的多少，与发生ＬＧＡ及ＳＧＡ有关。     

子宫肌瘤与肌肉组织雌孕激素受体含量与月经周期及子 …

应用放射受体分析法测定４０例子宫肌瘤患者子宫肌瘤、肌肉组织雌激素受体（ＥＲ）、孕激素受体（ＰＲ）的含量，月经周期根据月经史经子宫内膜组织相来判断，比较两种组织ＥＲ、ＰＲ含量与月经周期及子宫内膜组织相的关系。结果：子宫肌瘤组织的ＥＲ、ＰＲ含量高于同一子宫正常肌层的含量（Ｐ〈０．０５）；子宫肌瘤与肌肉两种组织中ＥＲ含量在子宫内膜增殖期高于分泌期（Ｐ〈０．０２５，Ｐ〈０．０５），ＰＲ含量分泌期高于增殖期     

A monoclonal antibody to a cell surface determinant in human endometrial epithelium: stage-specific expression in the menstrual cycle

A monoclonal antibody (CC25) was obtained after immunization of mice with intact glandular epithelial cells from secretory phase endometrium. Here we report a preliminary immunohistologic study in the endometrium of 29 patients in different phases of the menstrual cycle and early pregnancy. In immunofluorescence, CC25 binds to a basolaterally oriented epithelial cell surface antigen that is absent during the proliferative phase and appears suddenly in both glandular and uterine surface locations soon after ovulation. In mid and late secretory phase, the level of expression diminishes slowly. The epitope is absent from glandular epithelial cells in first-trimester decidua. However, it is associated with vascular smooth muscle cells in endometrium and decidua. CC25 promises to be a useful reagent for the analysis of endometrial function during the menstrual cycle.     

HOXA10的辅因子Meis1、Pbx1在人子宫内膜中的表达

目的:探讨HOXA10的两个辅因子Pbx1和Meis1在人正常子宫内膜中的表达及其变化规律。方法:采用原位杂交进行组织学定位,逆转录聚合酶链反应(RT-PCR)进行半定量,在mRNA水平上检测人正常月经周期子宫内膜中Pbx1和Meis1的表达水平。结果:Meis1在子宫内膜基质细胞和腺上皮细胞均有表达,其中腺上皮细胞的表达高于基质细胞;增生期Meis1仅有弱表达,分泌期显著增加(P<0.05),以分泌中期表达最强(P<0.05)。在整个月经周期中并未检测到Pbx1的表达。结论:Meis1作为HOXA10的辅因子,在人正常子宫内膜中规律性的表达,可能对HOXA10介导的胚胎着床发挥着重要作用。     

HOXA10基因在子宫内膜组织中的表达及与不孕的关系

目的　探讨HOXA10基因在正常育龄妇女及不明原因不孕患者子宫内膜中的表达 ,在着床过程中的作用及与不孕的关系。方法　采用原位杂交和逆转录聚合酶链反应 (RT PCR)技术 ,检测 5 2例正常育龄妇女及 38例不明原因不孕患者子宫内膜组织中HOXA10基因mRNA的表达。其中 ,正常育龄妇女子宫内膜周期为 10例增殖早期、10例增殖晚期、9例分泌早期、16例分泌中期、7例分泌晚期 ,不明原因不孕患者子宫内膜周期为增殖早期 7例、增殖晚期 8例、分泌早期 6例、分泌中期 11例、分泌晚期 6例。结果　 (1)HOXA10基因mRNA在正常育龄妇女子宫内膜腺体及间质中均有表达。原位杂交法检测 (以显色区灰度阳性单位表示 )显示 ,分泌中期腺体为 5 6 9± 0 5 7、间质为 7 48± 0 6 7,分泌晚期腺体为 5 99± 0 40、间质为 7 98± 1 0 8,显著高于增殖早期 (腺体 3 0 4± 0 30 ,间质3 2 5± 0 31)、晚期 (腺体 3 35± 0 2 0 ,间质 3 2 0± 0 37)和分泌早期 (腺体 3 0 7± 0 2 6 ,间质 3 18± 0 2 7)(P <0 0 1) ;分泌中、晚期间质表达高于腺体 (P <0 0 1)。RT PCR法检测显示 ,HOXA10基因mRNA表达 ,分泌中期为 (5 7 0± 3 4) %、晚期为 (5 6 2± 2 9) % ,显著高于增殖早期的 (31 8± 2 6 ) %、晚期的(32 2± 2 3) %和     

Activation antigens during the proliferative and secretory phases of endometrium and early-pregnancy decidua

BACKGROUND: Clarifying the normal distribution of activation antigens will contribute to database construction studies of monoclonal-antibody-based therapies in endometrial disorders. METHODS: In this study, endometrial tissue samples obtained during proliferative and secretory phases and decidual samples of early pregnancies were immunostained by the monoclonal antibodies anti-CD26, anti-CD30, anti-CD70, anti-CD71, and anti-CD98 using the indirect immunoperoxidase method. RESULTS: CD26 is expressed on the glandular epithelium in the endometrium and decidua. Endothelial CD26 is expressed less in the decidua when compared to the endometrium. CD30 is strongly expressed by decidual cells. It is only weakly expressed on endometrial and decidual vessels. Glandular and endothelial CD70 expression is mainly seen in the proliferative phase of the menstrual cycle. Glandular CD71 expression is less in the decidua when compared to the endometrium. Its expression on stromal cells is more in the secretory phase of the menstrual cycle and in early pregnancy deciduae. It is expressed on endometrial vessels but not on decidual vessels. Glandular CD98 is expressed more in the decidua when compared to the endometrium. This antigen exists on endometrial lymphocytes. It is strongly expressed on the endothelium in the endometrium and decidua. CONCLUSION: It seems that CD26 and CD70 are not involved in the functions of endometrial and decidual stromal cells. CD30 and CD71 are thought to be involved in decidualization. Absence of activation antigens other than CD98 on lymphocytes indicated an antigenic profile for large granular lymphocytes that is different from regular lymphocytes.     

CD44s expression is reduced in endometriotic lesions compared to eutopic endometrium in women with endometriosis.

Immunohistochemical expression of the standard form of CD44 (CD44s) was examined in archival formalin-fixed endometriotic and matching eutopic endometrial tissue obtained from 25 patients in proliferative (N = 16) and secretory (N = 9) stages of the cycle. CD44s was expressed in most eutopic endometria and endometriotic tissue. Its expression was significantly higher in secretory than in proliferative phase endometrium. It was low but detectable in 13 of 16 proliferative phase biopsies. The majority of these endometria exhibited both glandular and stromal staining (63%). In the secretory phase, glandular cells exhibited a significantly greater intensity of staining compared to stromal cells. In endometriotic tissue, stromal cell CD44s expression did not differ between tissue types in either stage of the cycle. In contrast, glandular expression in endometriotic tissue during the secretory phase was reduced (p < 0.05) compared to eutopic endometrium. It was absent in 66% of cases and reduced in the remaining cases. Our results indicate a correlation between CD44s expression and secretory differentiation of endometrial glands in the cycle, suggesting hormonal regulation of its expression. This cyclic pattern of CD44s expression was lost in corresponding endometriotic tissue. Reduced expression of CD44s in endometriotic tissue may provide insight into the pathophysiology of endometriosis.     

Hoxa-10在人月经周期分泌中期子宫内膜腺上皮表达下降

目的 :对同源异型框基因 Hoxa-1 0在月经周期各阶段人子宫内膜的表达形式进行观察。方法 :通过原位杂交方法测定了 5例增殖期、9例分泌期的人子宫内膜 Hoxa-1 0的表达。结果 :Hoxa-1 0基因在人子宫内膜均有表达。但在各周期阶段 ,其表达的强度和部位却有所不同。首次发现 Hoxa-1 0在对应于着床期的分泌中期以及分泌晚期子宫内膜腺上皮的表达明显降低或不表达。结论 :Hoxa-1 0在人类着床过程中可能具有重要功能。     

早孕蜕膜及绒毛组织中趋化因子CXC受体3、4及其配体的表达变化和意义

目的 探讨早孕蜕膜及绒毛组织中趋化因子CXC受体(CXCR)3、4及其配体CXCL9、CXCL10和CXCL12的表达变化和意义.方法 体外分离正常早孕蜕膜组织中单个核细胞,免疫磁珠分选试剂盒纯化CD+56自然杀伤(NK)细胞,流式细胞仪分析其纯度和表型;RT-PCR技术榆测早孕蜕膜NK细胞中CXCR3和CXCR4、早孕蜕膜及绒毛组织中CXCL9、CXCL10、CXCL12的表达情况;免疫组化链霉菌抗生物素蛋白-过氧化物酶连接(SP)法检测正常子宫内膜、早孕蜕膜组织中CXCL9和CXCL10的表达及CD+56NK细胞的分布情况,分析CXCL9、CXCL10表达量(灰度值)与CD+56NK细胞数的相关性.结果 分离纯化的早孕蜕膜NK细胞中,98.7%的细胞表型为CD56bright;早孕蜕膜NK细胞中有CXCR3和CXCR4表达;早孕蜕膜组织中有CXCL9、CXCL10表达,早孕绒毛组织中有CXCL12的表达.分泌期子宫内膜中CXC19、CXCL10表达最为56±43、59±47,较增生期子宫内膜的16±18、8±14明显升高,差异有统计学意义(P<0.05),而早孕蜕膜组织中CXCL9、CXCL10表达量为143±35、158±29,较分泌期子宫内膜进一步升高(P<0.05);分泌期子宫内膜中NK细胞数量为(60±20)个,增生期子宫内膜中NK细胞数量为(23±4)个,两者比较,差异有统计学意义(P<0.05),早孕蜕膜中NK细胞数量为(114 ±15)个,较分泌期子宫内膜进一步增多(P<0.05);子宫内膜和蜕膜组织中CXCL9、CXCL10表达量与组织中CD56+细胞数呈正相关关系(rcxL9=0.88,P<0.05;rcxcL10=0.86,P<0.05).结论 早孕蜕膜及绒毛组织中表达的CXCL9、CXCL10及CXCL12可能通过与CD56+NK细胞表面对应的趋化因子受体CXCR3、CXCR4结合而影响早孕期母-胎界面中CD56+NK细胞的聚集,从而对母-胎间免疫平衡起调控作用.     

A comparative study of nucleic acid content and electrophoretic analysis of human decidual and endometrial proteins

DNA, RNA and protein content expressed in terms of tissue wet weight was significantly reduced in decidua compared to endometrium. A protein with an approximate molecular weight of 36 000 was detected in higher incidence in decidua compared to normal endometrium. Another protein with a molecular weight of 26 000 was detected predominantly in decidua and secretory endometrium. Semiquantitative changes were also observed in the decidua. The peak area of one protein with a molecular weight of 48 000, which was significantly elevated in the secretory compared to the proliferative phase of the cycle, was significantly reduced in early pregnancy decidua. However, in term decidua the peak area of this protein was similar to those in endometrial tissue obtained in the luteal phase of the menstrual cycle. The results demonstrated that the transformation of endometrial stromal cells to decidua involves changes in nucleic acid and protein profiles and is accompanied by enhanced synthesis of at least one protein.     

Expression of Fox head protein 1 in human eutopic endometrium and endometriosis

The objective of this study is to examine the localization and expression of FOXP1 in human endometrium during the menstrual cycle and in endometriotic lesions and endometrial adenocarcinoma. FOXP1 protein expression was analyzed by immunohistochemistry and Western blot. FOXP1 expression was significantly different between glandular epithelial and stromal nuclei and cytoplasm in both endometrial functionalis and basalis. FOXP1 immunostaining was significantly reduced in the early secretory stage in comparison to the mid proliferative stage in the functionalis and the early proliferative stage in the basalis. FOXP1 expression was found in endometriotic lesions but not in endometrial adenocarcinoma. Multiple protein bands of FOXP1 were identified, and their presence varied considerably among patients. Protein expression levels were significantly higher in the mid and late secretory stages in comparison to early proliferative and early secretory stages. FOXP1 protein is present in human endometrium with evidence of cycle stage-dependent changes in expression.